Applications published 19 September 2007
Pharmaceutical formulations
Schering 1833461*
Pharmaceutical manufacturing process for heat sterilised glucocorticoid suspensions
Norton Healthcare 1833462*
Process for milling poorly soluble drugs in the presence of liquid propellants
Glaxo Group 1833463*
Solid pharmaceutical compsn valsartan
KRKA 1833464*
Lyophilisation of virosomes
Pevion Biotech 1833465*
Methods for the preparation of a stable pharmaceutical solid
Ranbaxy Laboratories 1833466*
Pharmaceutical compsns for sleep disorders
Collegium Pharmaceutical 1833467*
Tablet formulation for sustained drug-release
Universite de Montreal 1833468*
Pharmaceutical compsns of acid labile substances
Lupin 1833469*
Nanoparticulates for protein drug delivery
Nanomega Medical 1833470*
External patches containing etofenamate
Teikoku Seiyaku 1833471*
Use of certain biphenyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (MS)
Aventis Pharmaceuticals 1833472*
5HT2C receptor modulator compsns and methods of use
Arena Pharmaceuticals 1833473*
Pharmaceutical compsns based on fluorinated sulphamides and sulphinamides
Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; S3F Chimie Societe Chimique de Fabrication de Produits Fluores 1833474*
Use of resolvins to treat gastrointestinal diseases
The Brigham and Women's Hospital 1833475*
Extended release pharmaceutical compsns of celecoxib
Pliva Hrvatska; Pliva - Research and Development 1833476*
Pyrazolo-heteroaryl compounds, useful to treat TNF-alpha and IL-1 mediated diseases
Novartis 1833477*
Use of selected CGRP antagonists in combination with other antimigraine medical substances for the treatment of migraine
Boehringer Ingelheim 1833478*
1-(2-methylpropyl)-1H-imidazo 4,5-C(1,5)naphthyridin-4-amine ethane-sulfonate and 1-(2-methylpropyl)-1H-imidazoy 4,5-C 1,5 naphthyridin-4-amine methanesulphonate
Takeda Pharmaceutical Company 1833479*
Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
Artesian Therapeutics 1833480*
Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
Schering 1833481*
Compounds and therapeutical use thereof
Myriad Genetics 1833482*
Use of selected CGRP antagonists for controlling menopausal hot flashes
Boehringer Ingelheim International 1833483*
Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients
Boehringer Ingelheim International 1833484*
Prevention of thrombotic disorders with active vitamin D compounds or mimics thereof
Novacea 1833485*
Treatment products for animals and means for preparing same
Cardon Pharmaceuticals 1833486*
New use of Gabab receptor agonists
AstraZeneca 1833487*
Casein kinase-2-antisense therapy
Regents of the University of Minnesota; Sloper, Dan; Davis, Alan; Unger, Gretchen; Ahmed, Khalil; Slaton, Joel 1833488*
Glycolipids and analogues thereof as antigens for NK TY cells
The Rockefeller University; Scripps Clinic and Research Foundation 1833489*
RNAI modulation of RSV and therapeutic uses thereof
Alnylam Pharmaceuticals 1833490*
Topical compsns comprising one or more of 44-thiouridine, isomaltitol and uridine
Selectica Pharmaceuticals 1833491*
A new use for very low molecular weight heparins
Opocrin 1833492*
Use of polyethylene oxide for urogenital infection inhibition
Kimberley-Clark Worldwide 1833493*
Regeneration of pancreatic islets by amniotic fluid stem cell therapy
Wake Forest University Health Sciences 1833494*
Dermatologic use of milk proteins
Campina Nederland Holding 1833495*
Treatment of stroke and other acute neurodegenerative disorders using post partum derived cells
Ethicon 1833496*
Bacteriophage compsns
Canagen Life Sciences 1833497*
Oral compsn for enhancing skin properties
Unilever 1833498*
Homeopathic agent for the prophylaxis of diseases caused by parasites
Weineck, Andrea 1833499*
Method to enhance the bone formation activity of BMP by RUNX2 acetylation
Biorunx 1833500*
Laminin receptor binding molecule
Ambrilia Biopharma 1833501*
Pharmaceutical compsn for the treatment of invasive pulmonary aspergillosis
Council of Scientific & Industrial Research 1833502*
Pulmonary surfactant formulations
Discovery Laboratories 1833503*
Sustained delivery of PDGF using self-assembling peptide nanofibres
The Brigham & Women's Hospital 1833504*
Local treatment of bone defects with matrix releasing BMP or PTH
Kuros Biosurgery 1833505*
Use of compsns comprising various tumour-associated antigens as anti-cancer vaccines
Mannkind Corp 1833506*
Compsns for immunizing against mycobacterium
Isis Innovation 1833507*
Porcine reproductive and respiratory syndrome virus strains and compsns
Intervet International 1833508*
Delaying or preventing onset of muscular sclerosis
Biogen Idec 1833509*
Orally deliverable and anti-toxin antibodies and methods for making and using them
Progenics Pharmaceuticals (Nevada) 1833510*
Method of treating brain cancer
Myriad Genetics; Cytovia 1833511*
Optical imaging
GE Healthcare 1833512*
Use of cyanine dyes for the diagnosis of proliferative diseases
Bayer Schering Pharma 1833513*
Phospholipid ether analogues for detecting and treating cancer
Cellectar 1833514*
